RecruitingPhase 1NCT06874335

A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

A Phase 1, Multicenter, Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination With Other Anti-Cancer Agents in Adult Participants With Advanced or Metastatic Solid Tumors

Sponsor

Biohaven Therapeutics Ltd.

Enrollment

140 participants

Start Date

Mar 20, 2025

Study Type

INTERVENTIONAL

Conditions

Solid Tumor

Summary

This is a Phase 1, first in human (FIH), Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination with Other Anti-Cancer Agents in Adult Participants with Advanced or Metastatic Solid Tumors

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BHV-1530 for people with solid tumor. The study is currently recruiting participants at 13 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBHV-1530

BHV-1530 will be administered as an IV infusion on Day 1 of each 21-day cycle

DRUGCemiplimab

cemiplimab (350 mg) will be administered as an IV infusion on Day 1 of each 21-day cycle

Locations(17)

Site-111

Newport Beach, California, United States

Site-107

Denver, Colorado, United States

Site-108

Lake Mary, Florida, United States

Site-121

Miami, Florida, United States

Site-118

Orlando, Florida, United States

Site-120

Ann Arbor, Michigan, United States

Site-110

Detroit, Michigan, United States

Site-115

Durham, North Carolina, United States

Site-122

Cleveland, Ohio, United States

Site-112

Myrtle Beach, South Carolina, United States

Site-116

Nashville, Tennessee, United States

Site-103

Austin, Texas, United States

Site-104

Houston, Texas, United States

Site-101

Irving, Texas, United States

Site-105

San Antonio, Texas, United States

Site-106

West Valley City, Utah, United States

Site-102

Fairfax, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06874335

Related Trials

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

NCT0493961041 locations

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

NCT074893781 location

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

NCT064753001 location

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT0591926433 locations

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

NCT062340989 locations